Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 7,755 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Disease assessments Clear all
Completed Phase 2 Interventional Results available

Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00429793
View directory record Official record
Conditions
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 13, 2026, 8:06 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

The University of Oregon ACCESS Project

NCT07264621
View directory record Official record
Conditions
School Attendance, School Climate, School Engagement, School Exclusion, Externalizing Behavior, Disparities, Teacher-student Relationships, Stress, Emotional Regulation, Depression
Interventions
Inclusive Skill-building Learning Approach (ISLA), Family Check-Up Online (FCU-O), FCU-Online with telehealth coaching
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
11 Years and older
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
13
States / cities
Cottage Grove, Oregon • Eugene, Oregon • Springfield, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 13, 2026, 8:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peer-Led Dissonance Eating Disorder Prevention: Virtual Delivery

NCT04433247
View directory record Official record
Conditions
Eating Disorders
Interventions
Peer Led Group Intervention
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
16 Years to 26 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 13, 2026, 8:06 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program

NCT05368038
View directory record Official record
Conditions
Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease, GM1 Gangliosidosis, Gaucher Disease, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C
Interventions
Confirmatory Testing
Diagnostic Test
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Up to 4 Weeks
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
9
States / cities
Brooklyn, New York • Manhasset, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 13, 2026, 8:06 PM EDT
Terminated Phase 3 Interventional

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

NCT01950455
View directory record Official record
Conditions
Parkinson's Syndrome
Interventions
NAV5001
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 13, 2026, 8:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil

NCT00988585
View directory record Official record
Conditions
Heart Disease
Interventions
EPA 600, EPA 1800, Olive Oil, DHA
Dietary Supplement
Lead sponsor
Cardiovascular Research Associates
Network
Eligibility
21 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 13, 2026, 8:06 PM EDT
Completed No phase listed Observational

Spoken Discourse Biomarker of PD Cognitive Impairment

NCT05909163
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
50 Years to 90 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 13, 2026, 8:06 PM EDT
Not listed Phase 3 Interventional

Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor

NCT00724906
View directory record Official record
Conditions
Parkinsonian Syndromes
Interventions
123 I - ALTROPANE®
Drug
Lead sponsor
Alseres Pharmaceuticals, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hopkinton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 13, 2026, 8:06 PM EDT
Terminated Phase 2 Interventional Results available

Riluzole to Treat Depression in Bipolar Disorder

NCT00054704
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Riluzole, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 13, 2026, 8:06 PM EDT
Completed Not applicable Interventional

Evaluation of Web-based Transition Education to Enhance Transition Readiness

NCT03303248
View directory record Official record
Conditions
Congenital Heart Disease, Transition, Pediatric Congenital Heart Disease
Interventions
Web-based Educational Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 25 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 13, 2026, 8:06 PM EDT
Recruiting Not applicable Interventional

Evaluating WhatsOK Helpline for Youth With Concerns About Sexual Thoughts and Behaviors

NCT07525778
View directory record Official record
Conditions
Mental Health, Social Support, Perceived Self-efficacy, Sexual Behavior
Interventions
Contact helpline
Behavioral
Lead sponsor
Center for Violence Prevention Research Inc
Other
Eligibility
14 Years to 17 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 8:06 PM EDT
Terminated Not applicable Interventional

Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

NCT00456378
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
DIAM™ Spinal Stabilization System, Conservative care
Device · Procedure
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
29
States / cities
Scottsdale, Arizona • Beverly Hills, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 13, 2026, 8:06 PM EDT
Completed Phase 2 Interventional Results available

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

NCT00921115
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Fulvestrant, Anastrazole
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 13, 2026, 8:06 PM EDT
Completed Not applicable Interventional

Improving Sleep and Cognition in Alzheimer's Disease

NCT05200208
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Citicoline supplement, Placebo
Dietary Supplement · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 8:06 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study to Demonstrate That Muscle Pattern Recognition (MPR) is an Effective Evaluation Tool for Musculoskeletal Neck or Back Pain

NCT00134225
View directory record Official record
Conditions
Neck Pain, Low Back Pain
Interventions
Muscle Pattern Recognition (MPR)
Device
Lead sponsor
iTech Medical, Inc.
Industry
Eligibility
18 Years to 62 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
3
States / cities
Irvine, California • Portage, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 26, 2005 · Synced Oct 13, 2026, 8:06 PM EDT
Recruiting Not applicable Interventional

Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT05945121
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant
Interventions
Cardio-oncology program
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 13, 2026, 8:06 PM EDT
Recruiting Not applicable Interventional

Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease

NCT05831085
View directory record Official record
Conditions
Coronary Artery Stenosis
Interventions
State-of-the-Art Percutaneous Coronary Intervention, standard CABG
Procedure
Lead sponsor
Duk-Woo Park, MD
Other
Eligibility
20 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 13, 2026, 8:06 PM EDT
Recruiting Not applicable Interventional

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

NCT05131035
View directory record Official record
Conditions
Psychosis, Prodromal Schizophrenia, Prodromal Symptoms
Interventions
SCORES (Specific COgnitive Remediation with Support)
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
14 Years to 20 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 13, 2026, 8:06 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

NCT02138838
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Cinacalcet HCl, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 13, 2026, 8:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the El Camino Program

NCT06485284
View directory record Official record
Conditions
Sexual Behavior, Adolescent Behavior
Interventions
El Camino, Life skills program
Behavioral
Lead sponsor
Child Trends
Other
Eligibility
14 Years to 21 Years
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Gaithersburg, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 13, 2026, 8:06 PM EDT
Completed No phase listed Observational

PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients

NCT03342378
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oropharynx Cancer
Interventions
Intensity modulated radiotherapy (IMRT), PET-MRI
Radiation · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 13, 2026, 8:06 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT06754852
View directory record Official record
Conditions
Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Interventions
HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
Drug
Lead sponsor
Hemab ApS
Industry
Eligibility
16 Years to 69 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 13, 2026, 8:06 PM EDT
Recruiting Not applicable Interventional

The HOME Study (Healthy Options Made Easy): Telehealth Nutrition Sessions for People Living With Brain Injury

NCT05965947
View directory record Official record
Conditions
Brain Injuries
Interventions
Medical Nutrition Therapy
Behavioral
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 13, 2026, 8:06 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

NCT00891735
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
99
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 13, 2026, 8:06 PM EDT